SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Depotech(depo) -- Ignore unavailable to you. Want to Upgrade?


To: Sector Investor who wrote (439)12/15/1997 3:15:00 PM
From: Czechsinthemail  Respond to of 887
 
DEPO starting to come back to life. Trading up now. Volume has been low, so looks like the wait-and-see school is prevailing. Though with limited volume, any new buying could pop the price up.
Good luck to everyone.
Baird



To: Sector Investor who wrote (439)12/15/1997 4:22:00 PM
From: Czechsinthemail  Read Replies (1) | Respond to of 887
 
Sector,
This Cowan review is the most tepid I've seen on DepoCyt and may explain some of the cautious attitude going into the ODAC meeting on the 18th. Virtually everyone else suggests DepoCyt approval is pretty much a sure thing. I've seen more concern around how long the ultimate FDA approval may take and the effect that might have in delaying sales and profits.
For those new to DEPO, a trip to their website and to Zacks (where they have a perfect 1.0 rating based on four Strong Buy recommendations) might be useful.
Good luck to everyone,
Baird



To: Sector Investor who wrote (439)12/16/1997 9:16:00 AM
From: chirodoc  Read Replies (1) | Respond to of 887
 
<<<<<< Another look at the Phase III data and a chat with one of the investigators in the trial reinforced our view that while the data are not stellar, the drug will likely be approved based on its potential benefits to a patient population with limited treatment alternative

.......is there any more info on this report? thanks for sharing that with us!!!!!!